Morgan Stanley’s ARS Pharmaceuticals SPRY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.54M | Sell |
316,673
-235,691
| -43% | -$2.26M | ﹤0.01% | 4593 |
|
|
2025
Q4 | $6.44M | Sell |
552,364
-148,050
| -21% | -$1.44M | ﹤0.01% | 3989 |
|
|
2025
Q3 | $7.04M | Buy |
700,414
+316,798
| +83% | +$4.55M | ﹤0.01% | 3865 |
|
|
2025
Q2 | $6.69M | Sell |
383,616
-58,898
| -13% | -$850K | ﹤0.01% | 3811 |
|
|
2025
Q1 | $5.57M | Buy |
442,514
+9,911
| +2% | +$119K | ﹤0.01% | 3844 |
|
|
2024
Q4 | $4.56M | Sell |
432,603
-206,019
| -32% | -$2.89M | ﹤0.01% | 4076 |
|
|
2024
Q3 | $9.26M | Buy |
638,622
+504,816
| +377% | +$6M | ﹤0.01% | 3485 |
|
|
2024
Q2 | $1.14M | Buy |
133,806
+35,853
| +37% | +$318K | ﹤0.01% | 4883 |
|
|
2024
Q1 | $1M | Sell |
97,953
-117,873
| -55% | -$879K | ﹤0.01% | 4954 |
|
|
2023
Q4 | $1.18M | Buy |
215,826
+131,613
| +156% | +$577K | ﹤0.01% | 5223 |
|
|
2023
Q3 | $318K | Buy |
84,213
+23,534
| +39% | +$154K | ﹤0.01% | 5371 |
|
|
2023
Q2 | $407K | Sell |
60,679
-38,927
| -39% | -$260K | ﹤0.01% | 5315 |
|
|
2023
Q1 | $648K | Buy |
99,606
+10,392
| +12% | +$79.8K | ﹤0.01% | 5108 |
|
|
2022
Q4 | $761K | Buy |
89,214
+33,119
| +59% | +$215K | ﹤0.01% | 5016 |
|
|
2022
Q3 | $295K | Sell |
56,095
-181,512
| -76% | -$894K | ﹤0.01% | 5543 |
|
|
2022
Q2 | $1.01M | Sell |
237,607
-148,340
| -38% | -$517K | ﹤0.01% | 5010 |
|
|
2022
Q1 | $1.35M | Sell |
385,947
-1,004,963
| -72% | -$4.38M | ﹤0.01% | 4784 |
|
|
2021
Q4 | $9.26M | Buy |
1,390,910
+752,209
| +118% | +$6.11M | ﹤0.01% | 3024 |
|
|
2021
Q3 | $6.37M | Buy |
638,701
+625,477
| +4,730% | +$15.4M | ﹤0.01% | 3422 |
|
|
2021
Q2 | $408K | Buy |
+13,224
| New | +$424K | ﹤0.01% | 5652 |
|
|
2021
Q1 | – | Sell |
-2,365
| Closed | -$110K | – | 7554 |
|
|
2020
Q4 | $110K | Buy |
+2,365
| New | +$79K | ﹤0.01% | 5868 |
|
Other funds holding SPRY
RCM
O
RCMNY
DM
SOCM
